TW200633711A - Substituted pteridines for the treatment of inflammatory diseases - Google Patents
Substituted pteridines for the treatment of inflammatory diseasesInfo
- Publication number
- TW200633711A TW200633711A TW094141780A TW94141780A TW200633711A TW 200633711 A TW200633711 A TW 200633711A TW 094141780 A TW094141780 A TW 094141780A TW 94141780 A TW94141780 A TW 94141780A TW 200633711 A TW200633711 A TW 200633711A
- Authority
- TW
- Taiwan
- Prior art keywords
- treatment
- inflammatory diseases
- diseases
- substituted pteridines
- pteridines
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 150000003195 pteridines Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004057618A DE102004057618A1 (de) | 2004-11-29 | 2004-11-29 | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200633711A true TW200633711A (en) | 2006-10-01 |
Family
ID=35789067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094141780A TW200633711A (en) | 2004-11-29 | 2005-11-28 | Substituted pteridines for the treatment of inflammatory diseases |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7550472B2 (enExample) |
| EP (1) | EP1828189A1 (enExample) |
| JP (1) | JP2008521775A (enExample) |
| KR (1) | KR20070090975A (enExample) |
| CN (1) | CN101065382A (enExample) |
| AR (1) | AR054992A1 (enExample) |
| AU (1) | AU2005308785A1 (enExample) |
| BR (1) | BRPI0516626A (enExample) |
| CA (1) | CA2589209A1 (enExample) |
| DE (1) | DE102004057618A1 (enExample) |
| IL (2) | IL183447A0 (enExample) |
| MX (1) | MX2007006357A (enExample) |
| NZ (1) | NZ556152A (enExample) |
| RU (1) | RU2007124328A (enExample) |
| TW (1) | TW200633711A (enExample) |
| WO (1) | WO2006056607A1 (enExample) |
| ZA (1) | ZA200703125B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060198891A1 (en) | 2004-11-29 | 2006-09-07 | Francois Ravenelle | Solid formulations of liquid biologically active agents |
| DE102004057645A1 (de) * | 2004-11-29 | 2006-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057594A1 (de) * | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057595A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| WO2007135026A2 (de) | 2006-05-24 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Substituierte pteridine als therapeutika |
| JP5352452B2 (ja) * | 2006-06-06 | 2013-11-27 | メディシノバ， インコーポレイテッド | 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法 |
| WO2015120138A2 (en) * | 2014-02-05 | 2015-08-13 | Dana-Farber Cancer Institute, Inc. | AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF |
| LT3700529T (lt) | 2017-10-23 | 2025-10-10 | Naujas veikliųjų medžiagų derinys, skirtas progresuojančių fibrozinių intersticinių plaučių ligų (pf-ild) gydymui | |
| CN113876761B (zh) * | 2020-07-01 | 2022-12-20 | 广州华真医药科技有限公司 | 磷酸二酯酶4抑制剂ZL-n-91在制备抗骨肉瘤药物中的应用 |
| CA3234847A1 (en) | 2021-12-09 | 2023-06-15 | Boehringer Ingelheim International Gmbh | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases |
| PL4426298T3 (pl) | 2021-12-09 | 2026-07-20 | Boehringer Ingelheim International Gmbh | Nowe kombinacje terapeutyczne zawierające pirfenidon i inhibitor pde4 do leczenia postępujących włókniejących śródmiąższowych chorób płuc |
| CN119947728A (zh) | 2022-09-28 | 2025-05-06 | 勃林格殷格翰国际有限公司 | 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
| DE3323932A1 (de) | 1983-07-02 | 1985-01-10 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel |
| US4560685A (en) | 1984-06-18 | 1985-12-24 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | 2-Piperazino-pteridines useful as antithrombotics and antimetastatics |
| DE3445298A1 (de) | 1984-12-12 | 1986-06-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel |
| DE3540952C2 (de) | 1985-11-19 | 1997-08-14 | Thomae Gmbh Dr K | 2-Piperazino-pteridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| AU770551B2 (en) | 1998-12-28 | 2004-02-26 | 4-Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| DE10202468A1 (de) | 2002-01-23 | 2004-09-30 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung |
| DE102004057645A1 (de) | 2004-11-29 | 2006-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057594A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057595A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
-
2004
- 2004-11-29 DE DE102004057618A patent/DE102004057618A1/de not_active Withdrawn
-
2005
- 2005-11-18 US US11/282,535 patent/US7550472B2/en not_active Expired - Lifetime
- 2005-11-25 CN CNA2005800408289A patent/CN101065382A/zh active Pending
- 2005-11-25 AU AU2005308785A patent/AU2005308785A1/en not_active Abandoned
- 2005-11-25 JP JP2007541996A patent/JP2008521775A/ja active Pending
- 2005-11-25 AR ARP050104923A patent/AR054992A1/es unknown
- 2005-11-25 EP EP05813409A patent/EP1828189A1/de not_active Withdrawn
- 2005-11-25 KR KR1020077014857A patent/KR20070090975A/ko not_active Ceased
- 2005-11-25 RU RU2007124328/04A patent/RU2007124328A/ru not_active Application Discontinuation
- 2005-11-25 MX MX2007006357A patent/MX2007006357A/es active IP Right Grant
- 2005-11-25 NZ NZ556152A patent/NZ556152A/en not_active IP Right Cessation
- 2005-11-25 BR BRPI0516626-8A patent/BRPI0516626A/pt not_active IP Right Cessation
- 2005-11-25 CA CA002589209A patent/CA2589209A1/en not_active Abandoned
- 2005-11-25 WO PCT/EP2005/056247 patent/WO2006056607A1/de not_active Ceased
- 2005-11-28 TW TW094141780A patent/TW200633711A/zh unknown
-
2007
- 2007-04-13 ZA ZA200703125A patent/ZA200703125B/xx unknown
- 2007-05-28 IL IL183447A patent/IL183447A0/en unknown
-
2010
- 2010-12-09 IL IL209879A patent/IL209879A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7550472B2 (en) | 2009-06-23 |
| IL209879A0 (en) | 2011-02-28 |
| RU2007124328A (ru) | 2009-02-20 |
| JP2008521775A (ja) | 2008-06-26 |
| AR054992A1 (es) | 2007-08-01 |
| US20060116372A1 (en) | 2006-06-01 |
| MX2007006357A (es) | 2007-06-20 |
| CA2589209A1 (en) | 2006-06-01 |
| KR20070090975A (ko) | 2007-09-06 |
| IL183447A0 (en) | 2007-09-20 |
| NZ556152A (en) | 2009-06-26 |
| ZA200703125B (en) | 2008-09-25 |
| AU2005308785A1 (en) | 2006-06-01 |
| WO2006056607A8 (de) | 2007-01-18 |
| BRPI0516626A (pt) | 2008-09-16 |
| EP1828189A1 (de) | 2007-09-05 |
| WO2006056607A1 (de) | 2006-06-01 |
| CN101065382A (zh) | 2007-10-31 |
| DE102004057618A1 (de) | 2006-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200631583A (en) | Substituted pteridines for the treatment of inflammatory diseases | |
| WO2007135026A3 (de) | Substituierte pteridine als therapeutika | |
| UA93872C2 (ru) | Дигидротиенопиримидины для лечения воспалительных заболеваний | |
| TW200635597A (en) | Substituted pteridines for the treatment of inflammatory diseases | |
| WO2006058867A3 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
| UA101493C2 (ru) | Производные азетидина и циклобутана как ингибиторы jak | |
| MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
| TW200716546A (en) | Oxindole compounds and their uses as therapeutic agents | |
| MX2010004026A (es) | Piperidino-dihidrotienopirimidinas sustituidas. | |
| EA201290894A1 (ru) | Азетидиновые производные пиперидин-4-ила как ингибиторы jak1 | |
| MX2020012825A (es) | Compuestos multiciclicos y metodos de uso de los mismos. | |
| IL180979A0 (en) | Isoindoline compounds and methods of making and using the same | |
| TW200716596A (en) | Substituted amide derivatives and methods of use | |
| TW200724543A (en) | Heterocyclic compounds and their uses as therapeutic agents | |
| TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
| GEP20084452B (en) | Sulfonamide derivatives for the treatment of diseases | |
| MX2010000098A (es) | Derivados de guanina policiclicos y sus metodos de uso. | |
| MX2009009190A (es) | Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean. | |
| TW200611695A (en) | Pyrrolopyridine derivatives | |
| MX2010003269A (es) | Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. | |
| TW200745043A (en) | Substituted pyrazoline compounds, their preparation and use as medicaments | |
| EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
| MX2007006357A (es) | Pteridinas sustituidas para el tratamiento de enfermedades inflamatorias. | |
| TW200628473A (en) | Novel heterocycles | |
| TW200738699A (en) | 4-Substituted pyrazoline compounds, their preparation and use as medicaments |